Clinical trials: Lung Cancer, completed
Community Acquired Pneumonia, Pleuritis
Lung Ultrasound in Pleuritic Chest Pain
Chest pain is an alarming symptom and one of the most frequent causes of access to the Emergency Departement. Although chest X-ray remains an essential step in the diagnostic process, several studies showed numerous limitations…
- Conditions
- Community Acquired Pneumonia, Pleuritis, Pulmonary Embolism, Lung Cancer
- Trial name
- UPP (NCT02107001)
- Testing
- Lung ultrasound
- Where
- 7 sites in Italy
- Volunteers
- 400 people
- Sponsor
- University of Milan
Lung Cancer
Evaluation of the Archimedes™ System for Transparenchymal Nodule Access 2
The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs. This study is being conducted to confirm the performance of the Archimedes System in patients who are scheduled for standard…
- Trial name
- EAST2 (NCT02867371)
- Testing
- Archimedes System
- Where
- 10 sites in United States, China and 2 more
- Volunteers
- 166 people
- Sponsor
- Broncus Medical Inc
Lung Cancer
Women Helping Women - Lung Cancer Screening
The Women Helping Women Lung Cancer Screening (WHW-L) Study will be conducted to develop a scalable, easy to apply community-based intervention to increase rates of lung cancer screening and follow-up in high-need/low-resource…
- Trial name
- NCT04983134
- Testing
- Enhanced CHW Intervention
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Florida
Lung Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00032032
- Testing
- carboplatin, paclitaxel, radiation therapy
- Where
- 51 sites in United States
- Volunteers
- 69 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-small Cell Lung Cancer
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no…
- Trial name
- NCT03829332
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 162 sites in United States, Australia and 17 more
- Volunteers
- 623 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer Stage I
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS
CtDNA detection is a noninvasive detection method, and the second generation of high-throughput gene sequencing (NGS) is an important means of detecting ctDNA, which can detect trace ctDNA from smaller plasma samples.
- Trial name
- NCT03172156
- Testing
- ctDNA detection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Lung Cancer
Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with advanced lung cancer that…
- Trial name
- NCT00570401
- Testing
- dasatinib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Cancer
PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)
In this feasibility study, a zirconium-89 (89Zr)-avelumab positron emission tomography (PET) scan will be performed in 37 patients prior to treatment with avelumab to: 1.
- Trial name
- PINNACLE (NCT03514719)
- Testing
- 89Zr-avelumab PET, Avelumab
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Radboud University Medical Center
Malignant Pleural Mesothelioma
Intrapleural Gene Transfer for Pleural Mesothelioma
This research will study how to activate the immune system by using gene transfer. Gene transfer involves inserting a specially designed gene into cancer cells.
- Trial name
- IFN-alpha (NCT01212367)
- Testing
- SCH 721015
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Venous Thromboembolism, Lung Neoplasms
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
After any surgery, there is a risk of venous thromboembolism (VTE), including Deep Vein Thrombosis (DVT) in the major veins of the legs and Pulmonary Embolus (PE) in the lungs.
- Conditions
- Venous Thromboembolism, Lung Neoplasms, Pulmonary Embolism
- Trial name
- NCT02334007
- Testing
- LMWH: Dalteparin
- Where
- 2 sites in Canada
- Volunteers
- 102 people
- Sponsor
- McMaster University
Lung Cancer
Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these two treatments may kill more tumor cells.
- Trial name
- NCT00006470
- Testing
- monoclonal antibody 11D10 anti-idiotype vaccine, monoclonal antibody 3H1 anti-idiotype vaccine, radiation therapy
- Where
- 237 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Lung Cancer
Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment
The purpose of this study is to determine the percentage of patients with non-small cell lung cancer that will experience a shrinkage of their tumors following treatment with three medications given together: paclitaxel…
- Trial name
- NCT00807573
- Testing
- Paclitaxel, Pemetrexed, Bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Non-small Cell Lung Cancer, BRAF V600 Mutation
A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)
This study aims to describe the treatment patterns in clinical practice in adult patients with mNSCLC with a BRAF V600E mutation.
- Trial name
- NCT05546905
- Where
- 39 sites in France, Germany and 3 more
- Volunteers
- 206 people
- Sponsor
- Pierre Fabre Medicament
Interstitial Pulmonary Fibrosis ARDS, COPD (Chronic Obstructive Pulmonary Disease)
The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients
ECMO(Extracorporeal membrane oxygenation) is being essential for cardiopulmonary failure patients. There are two types of ECMO, which is veno-veno (V-V) that can be used in respiratory failure patients and veno-arterial (V-A)…
- Conditions
- Interstitial Pulmonary Fibrosis ARDS, COPD (Chronic Obstructive Pulmonary Disease), Bronchiectasis, Lymphangioleiomyomatosis
- Trial name
- NCT02859194
- Testing
- Veno-veno-arterial ECMO
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Yonsei University
Non-Small-Cell Lung Cancer
Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)
This is a two-arm, parallel, open-label, Phase 2 multicenter study of pemetrexed as first line combination therapy with either cisplatin or carboplatin in the palliative setting of stage IIIb and IV non-small cell lung cancer…
- Trial name
- NCT00402051
- Testing
- Pemetrexed, Cisplatin, Carboplatin
- Where
- 12 sites in Germany
- Volunteers
- 133 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC
To evaluate the safety of the proposed Phase II dosage of the investigational drug IMO 2055 when combined with erlotinib and bevacizumab in patients with previously treated advanced NSCLC.
- Trial name
- NCT00633529
- Testing
- IMO-2055
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- EMD Serono
Lung Cancer
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
The strategy for combining therapeutic agents in cancer treatments has been successful in multiple tumor types, including NSCLC. Erlotinib and bevacizumab target different pathways involved in tumor growth.
- Trial name
- NCT00367601
- Testing
- Erlotinib, Bevacizumab
- Where
- 13 sites in United States
- Volunteers
- 25 people
- Sponsor
- Nasser Hanna, M.D.
Precancerous Conditions, Carcinoma
Identification of a Plasma Proteomic Signature for Lung Cancer
The primary objective is to identify a panel of plasma and/or serum proteins that differentiates the absence or presence of lung malignancy in samples obtained from subjects enrolled in this IRB/EC approved study with pulmonary…
- Trial name
- NCT01752101
- Where
- 12 sites in United States
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- Integrated Diagnostics
Carcinoma, Non-Small Cell, Neoplasm Metastasis
A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor.
- Trial name
- NCT00728390
- Testing
- PF-00299804
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 74 people
- Sponsor
- Pfizer
Lung Cancer
Post-Treatment Surveillance in Lung Cancer
There are 13.7 million Americans currently living with a history of cancer. With continued improvements in cancer treatment and increasing life expectancy, this number is expected to reach nearly 18 million within the next…
- Trial name
- NCT03475420
- Volunteers
- 9,613 people
- Sponsor
- University of Virginia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.